文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

优化和验证 TZM-bl 测定法,用于标准化评估抗 HIV-1 的中和抗体。

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

机构信息

Department of Immunology, Duke University Medical Center, Durham, NC, United States; Department of Surgery, Duke University Medical Center, Durham, NC, United States.

Vaccine Research Center, National Institutes of Health (NIH), Bethesda, MD, United States.

出版信息

J Immunol Methods. 2014 Jul;409:131-46. doi: 10.1016/j.jim.2013.11.022. Epub 2013 Dec 1.


DOI:10.1016/j.jim.2013.11.022
PMID:24291345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4040342/
Abstract

The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. This assay has become the main endpoint neutralization assay used for the assessment of pre-clinical and clinical trial samples by a growing number of laboratories worldwide. Here we present the results of the formal optimization and validation of the TZM-bl assay, performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines. The assay was evaluated for specificity, accuracy, precision, limits of detection and quantitation, linearity, range and robustness. The validated manual TZM-bl assay was also adapted, optimized and qualified to an automated 384-well format.

摘要

TZM-bl 测定法可测量抗体介导的 HIV-1 中和作用,其作为在单次 Env 假型病毒感染后 HIV-1 Tat 调控的萤火虫荧光素酶(Luc)报告基因表达减少的函数。该测定法已成为全球越来越多的实验室用于评估临床前和临床试验样品的主要终点中和测定法。在这里,我们根据良好临床实验室实践(GCLP)指南,介绍了 TZM-bl 测定法的正式优化和验证结果。该测定法的特异性、准确性、精密度、检测限和定量限、线性、范围和稳健性进行了评估。经过验证的手动 TZM-bl 测定法也被改编、优化并适用于自动化 384 孔格式。

相似文献

[1]
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

J Immunol Methods. 2013-12-1

[2]
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.

J Immunol Methods. 2014-3-6

[3]
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

PLoS One. 2012-1-27

[4]
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

J Immunol Methods. 2011-9-22

[5]
Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals.

AIDS Res Hum Retroviruses. 2013-3

[6]
Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.

J Immunol Methods. 2013-11-28

[7]
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

J Virol. 2014-3

[8]
Measuring HIV neutralization in a luciferase reporter gene assay.

Methods Mol Biol. 2009

[9]
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

J Virol. 2005-8

[10]
Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.

Hum Vaccin Immunother. 2017-10-18

引用本文的文献

[1]
Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions.

bioRxiv. 2025-7-27

[2]
HIV-1 Vpu interacts with RBM10 to promote HIV-1 infection.

mSystems. 2025-8-19

[3]
Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines.

NPJ Vaccines. 2025-7-17

[4]
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

bioRxiv. 2025-7-10

[5]
Placenta - A Competent, But Not Infallible, Antiviral and Antiparasitic Barrier.

Reprod Sci. 2025-7-14

[6]
High-throughput High Content Quantification of HIV-1 Viral Infectious Output.

bioRxiv. 2025-7-1

[7]
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.

ACS Chem Biol. 2025-7-18

[8]
Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.

Cell Rep. 2025-6-24

[9]
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.

Lancet HIV. 2025-6

[10]
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning.

Nat Commun. 2025-5-18

本文引用的文献

[1]
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.

PLoS One. 2013-11-28

[2]
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

J Infect Dis. 2012-5-25

[3]
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

PLoS One. 2012-1-27

[4]
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

J Immunol Methods. 2011-9-22

[5]
LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays.

BMC Immunol. 2011-5-27

[6]
Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.

AIDS Res Hum Retroviruses. 2010-3

[7]
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

J Virol. 2009-11-25

[8]
Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.

PLoS Med. 2009-5-26

[9]
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1.

J Virol. 2009-8

[10]
International network for comparison of HIV neutralization assays: the NeutNet report.

PLoS One. 2009

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索